Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 4 recruiting now later-stage tilt small index

Skin Laxity: later-stage trial registry

4 of 11 indexed Skin Laxity trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #1,577 of 28,707 conditions by registered trial count.

11 US clinical trials · 4 currently recruiting · #1,577 of 28,707 conditions by registered trial count

Skin Laxity: 11 US clinical trials tracked, 4 recruiting.

Skin Laxity is the subject of 11 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Ulthera, running 3 of these trials.

Enrollment posture brief

Registry condition skin-laxity

OPEN 4 | RECR 36% | LATE 1 | EARLY 0 | RANK #1577 | SPON 3

Nearest open-share peer: Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (36% recruiting · 11 trials)

Acute Pancreatitis81.8%Acute Stroke45.5%Acquired Brain Injury36.4%Skin Laxity (this)36%Acute Lung Injury9.1%
Open-enrollment share among volume-matched conditions near Skin Laxity

Skin Laxity lists 4 open slots (36% of 11 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Skin Laxity on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Skin Laxity is recruiting below its size-band peers.

    4 of 11 indexed trials (36.4%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Skin Laxity research.

    Ulthera accounts for 3 of 11 trials (27.3%). 8 distinct sponsors appear on at least one study for this condition label.

  3. Most Skin Laxity trials plan to enrol fewer than 100 people.

    Median target enrolment is 35 among the 11 trials that report a genuine target (sentinel values excluded). 8 of those (72.7%) plan for fewer than 100 participants.

  4. Skin Laxity research is mostly interventional.

    10 interventional and 1 observational studies make up this index (90.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 31

Open and recent trials

11 total, page 1 of 1

RECRUITING NA 1,000 participants

Evaluation of Fractional Ablative Laser Treatment for Skin Conditions

Sciton

NCT05750901

RECRUITING NA 35 participants

An Evaluation of the Erchonia Laser As a Non-Invasive Treatment to Improve the Appearance of Skin Laxity

Erchonia Corporation

NCT06941610

RECRUITING NA 25 participants

A Study to Characterize Human Skin Changes From Biostimulator Treatments Via Non-invasive Imaging

Galderma R&D

NCT07399028

RECRUITING 10 participants

Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists

Cytrellis Biosystems

NCT07224880

ACTIVE NOT RECRUITING NA 500 participants

Clinical Feasibility Study to Evaluate the Safety and Performance of the Profound Matrix System

Candela Corporation

NCT06157567

ACTIVE NOT RECRUITING NA 200 participants

AV-23-001 AVAVA MIRIA Pilot Study

AVAVA

NCT06557434

ACTIVE NOT RECRUITING NA 40 participants

Evaluation of the Effects of a Biostimulator and Dermal Fillers for Cheek Augmentation and Contour Deficiencies

Galderma R&D

NCT06351358

COMPLETED Phase 3 45 participants

Safety and Efficacy of Sofwave Treatment to Lift Lax Skin

Sofwave Medical

NCT04829227

COMPLETED NA 31 participants

Feasibility Study: Ulthera Treatment of the Buttocks and Thighs

Ulthera

NCT01708460

COMPLETED NA 21 participants

Feasibility Study: Lifting and Tightening of the Elbows

Ulthera

NCT01708382

COMPLETED NA 2 participants

Feasibility Study: Heavy Water Tissue Labeling Protocol

Ulthera

NCT01708525

Phase Distribution

PhaseTrial count
Phase 3 1

Top Sponsors

Ulthera 3 trials
Galderma R&D 2 trials
Sciton 1 trials
Sofwave Medical 1 trials
AVAVA 1 trials

Named interventions

Most-linked intervention names on Skin Laxity records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Ulthera System Treatment Device
2 trials
Heavy Water Other
1 trials
Ulthera® System Treatment Device
1 trials
Restylane Treatment Device
1 trials
Sculptra treatment Device
1 trials
Profound Matrix Device
1 trials
MIRIA Device
1 trials
ellacor Device
1 trials

US sites by state

Facility locations filed on Skin Laxity trials. A trial with sites in several states counts in each.

New York 5 trials
Florida 3 trials
Virginia 2 trials
California 2 trials
Tennessee 1 trials
New Jersey 1 trials
North Carolina 1 trials
Massachusetts 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Skin Laxity page

11 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 4 Skin Laxity trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Ulthera sponsors the most Skin Laxity trials on record, review their full trial history before evaluating a specific study. See Ulthera's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Skin Laxity condition card totals 11 registered trials; most-linked intervention Ulthera System Treatment; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.